翟相涛

目的：探讨甲磺酸倍他司汀片联合盐酸氟桂利嗪胶囊治疗耳石症复位残留眩晕的临床疗效。方法：采用前瞻性随机对照研究将120例符合耳石症标准的患者纳入研究，其中男性48例，女性72例，男女比例=2:3，年龄39-81岁，平均（59.81±12.08）岁。依研究方案分为治疗组（口服甲磺酸倍他司汀片联合盐酸氟桂利嗪胶囊）60例与对照组（口服甲磺酸倍他司汀片）60例。记录两组患者治疗前后眩晕相关指标、有效率、复发率进行评价与统计学分析，比较两组的疗效差异。结果：两组患者治疗前DHI评分、恶心及呕吐发生率的比较差异无统计学意义（P>0.05）；两组患者治疗后头晕持续时间、治疗后3d、2周、1个月的DHI评分、治疗后BBS评分、有效率、复发率比较均存在统计学意义（均P<0.05）。结论：甲磺酸倍他司汀联合盐酸氟桂利嗪胶囊治疗耳石症手法复位后残留眩晕疗效突出，复发率以及不良反应发生率较低，临床可推广使用。

耳石症；甲磺酸倍他司汀片；盐酸氟桂利嗪胶囊；手法复位后；疗效观察

[1] 陈默,刘宇.观察手法复位治疗耳石症眩晕的有效性和安全性[J].中国医学文摘(耳鼻咽喉科学),2020,35(06):521-523. [2] 杨俊影,徐鹏程,张群,云宗金.基于 SRM-Ⅳ型眩晕诊疗系统的 BPPV 患者临床特征分析[J].医学信息,2021,34(23):73-76. [3] Kim HJ, Park J, Kim JS. Update on benign paroxysmal positional vertigo. J Neurol. 2021 May;268(5):1995-2000. doi: 10.1007/s00415-020-10314-7. Epub 2020 Nov 24. Erratum in: J Neurol. 2021 Feb 23. [4] Curthoys IS, Smith PF, de Miguel AR. Why Should Constant Stimulation of Saccular Afferents Modify the Posture and Gait of Patients with Bilateral Vestibular Dysfunction? The Saccular Substitution Hypothesis. J Clin Med. 2022 Feb 21;11(4):1132. [5] Kojima T, Oishi N, Nishiyama T, etc. Severity of Tinnitus Distress Negatively Impacts Quality of Life in Patients With Vestibular Schwannoma and Mimics Primary Tinnitus. Front Neurol. 2019 Apr 24;10:389. [6] 马秀玲.探讨手法复位联合药物治疗耳石症(良性阵发性位置性眩晕)的方法和疗效[J].世界复合医学,2020,6(07):4-6. [7] Palmeri R, Kumar A. Benign Paroxysmal Positional Vertigo. 2022 Jan 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. [8] Shivarkar NA, Dudhe PB, Nagras MA. Development and Validation of a HPTLC Method for Simultaneous Quantitation of Flunarizine Dihydrochloride and Propranolol Hydrochloride in Capsule Dosage Form. Indian J Pharm Sci. 2013 May;75(3):364-8. [9] Cao K, Han F, Lin A,etc . Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial. BMC Complement Altern Med. 2016 Sep 13;16(1):356.

点击下载PDF